Targeting beta-cell failure in lean patients with type 2 diabetes

niversity of Leeds0 个研究点目标入组 56 人开始时间: 2020年3月16日最近更新: 2021年10月4日

适应症

试验速览

暂无简介。

•Lean cohort:
•1. Men and women >18 years of age
•2. Normal body weight 18.5 = BMI =25 kg/m²
•3. T2D patients can be on treatment with oral glucose-lowering therapies, and if they are, they must have been on these treatments for at least 12 weeks prior to screening
•4. 6.5 = HBA1c = 10% at screening
•5. Agreement to maintain prior diet and exercise habits for the duration of the study
•Overweight cohort:
•1. Men and women >18 years of age
•2. Increased body weight BMI >27 kg/m²
•3. T2D patients can be on treatment with oral glucose-lowering therapies, and if they are, they must have been on these treatments for at least 12 weeks prior to screening
•4. 6.5 = HBA1c = 10% at screening
•5. Agreement to maintain prior diet and exercise habits for the duration of the study

•All cohorts:
•1. Any type of diabetes other than T2D
•2. Past history of significant CAD
•3. Known HF
•4. Significant renal impairment (eGFR< 30ml/min/m²)
•5. Participation in a clinical trial of an investigational medicinal product in the preceding 12 weeks
•6. Known hypersensitivity to dobutamine or gadolinium or any other contra-indications to MRI
•7. Participants with obesity where their girth exceeds the scanner bore
•8. History of pancreatitis
•9. Any history of liver disease
•10. Patients with Multiple Endocrine Neoplasia syndrome type 2
•11. Prior or current use of thiazolidinediones (aka PPAR-gamma agonists), fibrates, GLP-1RA or insulin
•12. Patients with high serum calcitonin levels at baseline
•13. Patients that are pregnant (female participants only)
•14. Inflammatory bowel disease
•15. Diabetic gastroparesis

发起方

niversity of Leeds